Human Antibodies to BMP6 for Iron-Deficiency Treatment
Summary
USPTO granted Regeneron Pharmaceuticals a patent (US12612452B2) for fully human antibodies targeting bone morphogenetic protein 6 (BMP6), with 14 claims. The antibodies inhibit BMP6 binding to the hemojuvelin receptor, reducing hepcidin transcription and expression to treat iron-deficiency anemia and related disorders. The application (17617657) was filed on June 9, 2020.
“The present invention provides antibodies that bind to BMP6, and methods of use.”
About this source
Granted patents in USPTO classification C07K, covering peptides, proteins, antibodies, and related biological molecules. Around 160 grants a month, each with the patent number, title, applicant, inventor names, and full abstract. Unlike published applications (which reveal in-progress research), grants are enforceable rights and signal what a company can now litigate or license. Watch this if you run an antibody or protein biologics program, advise on patent portfolio strategy for biologics companies, scout for licensing opportunities on recently granted claims, or track which research institutions are converting their early peptide work into issued patents.
What changed
USPTO granted Regeneron Pharmaceuticals a patent for human antibodies that bind BMP6 and inhibit hepcidin expression, providing a method for treating iron-deficiency anemia. The patent covers 14 claims including antibody compositions and methods of use for down-regulating hepcidin transcription.
Pharmaceutical and biotechnology companies developing treatments for iron-related disorders should review this patent to assess potential freedom-to-operate considerations or licensing opportunities. Competitors in the anemia treatment space should monitor Regeneron's patent portfolio for related BMP6/hepcidin pathway inventions.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Human antibodies to bone morphogenetic protein 6
Grant US12612452B2 Kind: B2 Apr 28, 2026
Assignee
Regeneron Pharmaceuticals, Inc.
Inventors
Sarah J. Hatsell, Vincent J. Idone, Andrew J. Murphy
Abstract
The present invention provides antibodies that bind to BMP6, and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to BMP6. The antibodies of the invention are useful for inhibiting binding of BMP6 to the hemojuvelin receptor, thereby down-regulating transcription and expression of hepcidin, thus providing a means of preventing or treating an iron-deficiency anemia or an iron-deficiency related disorder. In some embodiments, the antibodies of the present invention are used in treating at least one symptom or complication of an iron-deficiency anemia or an iron-deficiency related disorder.
CPC Classifications
C07K 16/22 C07K 2317/21 C07K 2317/92 C07K 2317/33 C07K 2317/76 A61K 9/0019 A61K 47/42 A61K 2039/505 A61P 7/06
Filing Date
2020-06-09
Application No.
17617657
Claims
14
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.